S&P 500   4,273.79
DOW   33,562.86
QQQ   354.90
Is Verizon’s 7% Yield Too Good To Pass Up?
The “Amazon Secret Royalty Program” Can Help Anyone Retire Like Royalty (Ad)
Surging Over 100%: Small Cap Electric Boat Maker Makes Waves
The Most Upgraded Stocks In May Are Moving Higher 
The “Amazon Secret Royalty Program” Can Help Anyone Retire Like Royalty (Ad)
Will Nvidia Be the Lifeline Intel Desperately Needs?
Here’s Why Disney’s MCU is Sinking in Quicksand
The “Amazon Secret Royalty Program” Can Help Anyone Retire Like Royalty (Ad)
Buffett-Backed BYD Caught In The Chinese Government's Stimulus
Here’s What Driving the 125% YTD Gains for Upstart Holdings Stock
S&P 500   4,273.79
DOW   33,562.86
QQQ   354.90
Is Verizon’s 7% Yield Too Good To Pass Up?
The “Amazon Secret Royalty Program” Can Help Anyone Retire Like Royalty (Ad)
Surging Over 100%: Small Cap Electric Boat Maker Makes Waves
The Most Upgraded Stocks In May Are Moving Higher 
The “Amazon Secret Royalty Program” Can Help Anyone Retire Like Royalty (Ad)
Will Nvidia Be the Lifeline Intel Desperately Needs?
Here’s Why Disney’s MCU is Sinking in Quicksand
The “Amazon Secret Royalty Program” Can Help Anyone Retire Like Royalty (Ad)
Buffett-Backed BYD Caught In The Chinese Government's Stimulus
Here’s What Driving the 125% YTD Gains for Upstart Holdings Stock
S&P 500   4,273.79
DOW   33,562.86
QQQ   354.90
Is Verizon’s 7% Yield Too Good To Pass Up?
The “Amazon Secret Royalty Program” Can Help Anyone Retire Like Royalty (Ad)
Surging Over 100%: Small Cap Electric Boat Maker Makes Waves
The Most Upgraded Stocks In May Are Moving Higher 
The “Amazon Secret Royalty Program” Can Help Anyone Retire Like Royalty (Ad)
Will Nvidia Be the Lifeline Intel Desperately Needs?
Here’s Why Disney’s MCU is Sinking in Quicksand
The “Amazon Secret Royalty Program” Can Help Anyone Retire Like Royalty (Ad)
Buffett-Backed BYD Caught In The Chinese Government's Stimulus
Here’s What Driving the 125% YTD Gains for Upstart Holdings Stock
S&P 500   4,273.79
DOW   33,562.86
QQQ   354.90
Is Verizon’s 7% Yield Too Good To Pass Up?
The “Amazon Secret Royalty Program” Can Help Anyone Retire Like Royalty (Ad)
Surging Over 100%: Small Cap Electric Boat Maker Makes Waves
The Most Upgraded Stocks In May Are Moving Higher 
The “Amazon Secret Royalty Program” Can Help Anyone Retire Like Royalty (Ad)
Will Nvidia Be the Lifeline Intel Desperately Needs?
Here’s Why Disney’s MCU is Sinking in Quicksand
The “Amazon Secret Royalty Program” Can Help Anyone Retire Like Royalty (Ad)
Buffett-Backed BYD Caught In The Chinese Government's Stimulus
Here’s What Driving the 125% YTD Gains for Upstart Holdings Stock
NASDAQ:AVDL

Avadel Pharmaceuticals (AVDL) Stock Forecast, Price & News

$14.40
+0.30 (+2.13%)
(As of 06/5/2023 ET)
Compare
Today's Range
$13.75
$14.66
50-Day Range
$8.48
$15.50
52-Week Range
$2.12
$15.82
Volume
580,959 shs
Average Volume
741,573 shs
Market Capitalization
$1.11 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.44

Avadel Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
6.7% Downside
$13.44 Price Target
Short Interest
Healthy
4.36% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.97mentions of Avadel Pharmaceuticals in the last 14 days
Based on 7 Articles This Week
Insider Trading
Acquiring Shares
$36,900 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($1.29) to ($0.35) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.78 out of 5 stars

Medical Sector

156th out of 986 stocks

Pharmaceutical Preparations Industry

64th out of 478 stocks


AVDL stock logo

About Avadel Pharmaceuticals (NASDAQ:AVDL) Stock

Avadel Pharmaceuticals Plc engages in the development and commercialization of pharmaceutical products. Its products include Bloxiverz, Vazculep, Nouress, and Akovaz. It focuses on the approval of FT218, a formulation of sodium oxybate designed to treat excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was founded in 1990 and is headquartered in Dublin, Ireland.

Receive AVDL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Avadel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

AVDL Stock News Headlines

Famous Wall Street Crash System Flashes RED
Hundreds of banks, hedge funds, and brokerages have paid $5,000 a month to access these alerts. Because when this system flashes on U.S. stocks, huge gains – and losses – can follow.
Avadel Pharmaceuticals (NASDAQ:AVDL) Shares Up 4.6%
What 11 Analyst Ratings Have To Say About Avadel Pharmaceuticals
Famous Wall Street Crash System Flashes RED
Hundreds of banks, hedge funds, and brokerages have paid $5,000 a month to access these alerts. Because when this system flashes on U.S. stocks, huge gains – and losses – can follow.
Avadel Pharmaceuticals (NASDAQ:AVDL) Trading Down 3.8%
Why Shares of Avadel Soared This Week
Avadel Pharmaceuticals (NASDAQ:AVDL) PT Raised to $14.00
Avadel Pharmaceuticals (NASDAQ:AVDL) PT Raised to $16.00
Analyst Expectations for Avadel Pharmaceuticals's Future
See More Headlines

AVDL Price History

AVDL Company Calendar

Last Earnings
3/30/2023
Today
6/05/2023
Next Earnings (Estimated)
8/08/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AVDL
Employees
66
Year Founded
2015

Price Target and Rating

Average Stock Price Forecast
$13.44
High Stock Price Forecast
$20.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
-6.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
7 Analysts

Profitability

Net Income
$-137,460,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$22.33 million
Book Value
($0.34) per share

Miscellaneous

Free Float
73,697,000
Market Cap
$1.11 billion
Optionable
Optionable
Beta
1.43

Social Links


Key Executives

  • Gregory J. Divis
    Chief Executive Officer & Director
  • Scott Macke
    Vice President-Supply Chain & Operations
  • Thomas S. McHugh
    Chief Financial Officer & Senior Vice President
  • Jason Vaughn
    Senior Vice President-Technical Operations
  • Jennifer Gudeman
    Vice President-Medical & Clinical Affairs













AVDL Stock - Frequently Asked Questions

Should I buy or sell Avadel Pharmaceuticals stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Avadel Pharmaceuticals in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AVDL shares.
View AVDL analyst ratings
or view top-rated stocks.

What is Avadel Pharmaceuticals' stock price forecast for 2023?

7 Wall Street research analysts have issued 1 year target prices for Avadel Pharmaceuticals' shares. Their AVDL share price forecasts range from $5.00 to $20.00. On average, they predict the company's stock price to reach $13.44 in the next twelve months. This suggests that the stock has a possible downside of 6.7%.
View analysts price targets for AVDL
or view top-rated stocks among Wall Street analysts.

How have AVDL shares performed in 2023?

Avadel Pharmaceuticals' stock was trading at $7.16 at the start of the year. Since then, AVDL stock has increased by 101.1% and is now trading at $14.40.
View the best growth stocks for 2023 here
.

Are investors shorting Avadel Pharmaceuticals?

Avadel Pharmaceuticals saw a drop in short interest in the month of May. As of May 15th, there was short interest totaling 3,350,000 shares, a drop of 13.9% from the April 30th total of 3,890,000 shares. Based on an average daily trading volume, of 916,600 shares, the days-to-cover ratio is presently 3.7 days.
View Avadel Pharmaceuticals' Short Interest
.

When is Avadel Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023.
View our AVDL earnings forecast
.

How were Avadel Pharmaceuticals' earnings last quarter?

Avadel Pharmaceuticals plc (NASDAQ:AVDL) posted its quarterly earnings data on Thursday, March, 30th. The company reported ($0.44) EPS for the quarter, missing the consensus estimate of ($0.30) by $0.14.

What ETFs hold Avadel Pharmaceuticals' stock?
What other stocks do shareholders of Avadel Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Avadel Pharmaceuticals investors own include Intelsat (I), Bank of America (BAC), Fossil Group (FOSL), Ciena (CIEN), AMC Entertainment (AMC), Chaarat Gold (CGH), Associated British Foods (ABF), Apollo Global Management (APO), Amarin (AMRN) and Cypress Semiconductor (CY).

What is Avadel Pharmaceuticals' stock symbol?

Avadel Pharmaceuticals trades on the NASDAQ under the ticker symbol "AVDL."

Who are Avadel Pharmaceuticals' major shareholders?

Avadel Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include Gendell Jeffrey L (6.83%), Wealth Effects LLC (3.22%), Brandes Investment Partners LP (1.86%), Samsara BioCapital LLC (1.82%), Renaissance Technologies LLC (1.06%) and Bank of America Corp DE (0.89%). Insiders that own company stock include Eric J Ende, Gregory J Divis, Linda Palczuk, Mark Anthony Mccamish and Thomas S Mchugh.
View institutional ownership trends
.

How do I buy shares of Avadel Pharmaceuticals?

Shares of AVDL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Avadel Pharmaceuticals' stock price today?

One share of AVDL stock can currently be purchased for approximately $14.40.

How much money does Avadel Pharmaceuticals make?

Avadel Pharmaceuticals (NASDAQ:AVDL) has a market capitalization of $1.11 billion and generates $22.33 million in revenue each year. The company earns $-137,460,000.00 in net income (profit) each year or ($2.32) on an earnings per share basis.

How can I contact Avadel Pharmaceuticals?

Avadel Pharmaceuticals' mailing address is 10 EARLSFORT TERRACE, DUBLIN L2, D02. The official website for the company is www.avadel.com. The company can be reached via phone at (531) 901-5201, via email at investors@avadel.com, or via fax at 353-1526-1077.

This page (NASDAQ:AVDL) was last updated on 6/6/2023 by MarketBeat.com Staff

My Account -